Immunovant Competitors

IMVT -  USA Stock  

USD 8.27  0.20  2.36%

Immunovant competes with Brickell Biotech, Bellus Health, Mustang Bio, Bridgebio Pharma, and Moleculin Biotech; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Immunovant competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Immunovant to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Immunovant competition on your existing holdings. Please see Immunovant Correlation with its peers.

Immunovant Competition 

 
Refresh
Return on Average Assets is likely to drop to -0.29 in 2021. Return on Average Equity is likely to drop to -0.31 in 2021. Immunovant Total Assets are comparatively stable at the moment as compared to the past year. Immunovant reported Total Assets of 412.49 Million in 2020. Current Assets is likely to gain to about 441.3 M in 2021, whereas Tangible Assets Book Value per Share are likely to drop 3.99 in 2021.

Specify up to 10 symbols:

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Immunovant's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Immunovant in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
3.788.1912.60
Details
Intrinsic
Valuation
LowReal ValueHigh
7.2711.6816.09
Details
Naive
Forecast
LowNext ValueHigh
3.207.6212.03
Details
8 Analysts
Consensus
LowTarget PriceHigh
10.0022.8661.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Immunovant. Your research has to be compared to or analyzed against Immunovant's peers to derive any actionable benefits. When done correctly, Immunovant's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Immunovant.

Immunovant Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Immunovant and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Immunovant and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Immunovant does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Immunovant Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Immunovant stock performing well and Immunovant company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Immunovant's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
BBI
 2.38 (0.23)  0.00  0.64  0.00 (0.09)  0.00  5.97 (4.35)  15.32 
BLU
 3.01  1.21  0.27  1.85  2.85  0.25 (3.44)  8.28 (5.41)  31.73 
MBIO
 2.43 (0.44)  0.00 (0.53)  0.00 (0.14)  0.00  4.44 (4.47)  17.27 
BBIO
 2.10 (0.43)  0.00 (0.73)  0.00 (0.16)  0.00  4.14 (4.56)  11.81 
MBRX
 1.99 (0.24)  0.00 (0.40)  0.00 (0.09)  0.00  4.53 (5.26)  12.09 
FOLD
 2.24  0.19  0.07  0.15  2.64  0.08 (2.24)  3.93 (4.59)  11.79 
BCAB
 2.34 (0.52)  0.00 (0.25)  0.00 (0.17)  0.00  4.23 (5.62)  12.26 
BCDA
 2.56 (0.31)  0.00 (0.28)  0.00 (0.08)  0.00  6.45 (6.25)  21.51 
BCLI
 2.32 (0.09)  0.00 (0.25)  0.00 (0.0311)  0.00  5.49 (3.68)  22.56 

Cross Equities Net Income Analysis

Compare Immunovant and related stocks such as Brickell Biotech, Bellus Health, Mustang Bio, Bridgebio Pharma, Moleculin Biotech, Amicus Therapeutics, Bioatla, Biocardia, and Brainstorm Cell Net Income Over Time
Select Fundamental

201020112012201320142015201620172018201920202021
BBI
(30.4 M)(7.3 M)(22.9 M)(31.2 M)(16.5 M)(9.2 M)(9 M)(13 M)(9.2 M)(23.9 M)(20.9 M)(22.6 M)
BLU
(1.9 M)(1.9 M)(1.9 M)(1.9 M)(1.9 M)(1.9 M)(1.9 M)(1.9 M)(9.1 M)(26 M)(31.8 M)(32.6 M)
MBIO
(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(12.7 M)(31.3 M)(30.7 M)(46.4 M)(60 M)(61.6 M)
BBIO
(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(130.7 M)(260.6 M)(448.7 M)(460.5 M)
MBRX
(1.8 M)(1.8 M)(1.8 M)(1.8 M)(1.8 M)(365.8 K)(3.9 M)(9.8 M)(11.9 M)(13.2 M)(17.4 M)(17.8 M)
FOLD
(54.9 M)(44.4 M)(48.8 M)(59.6 M)(68.9 M)(132.1 M)(200 M)(284 M)(349 M)(356.4 M)(276.9 M)(284.1 M)
BCAB
(29 M)(29 M)(29 M)(29 M)(29 M)(29 M)(29 M)(29 M)(29 M)(29.8 M)(35.9 M)(38.7 M)
BCDA
(11.5 M)9.7 M305 K19 K234 K(6.7 M)(10.3 M)(12.3 M)(14 M)(14.7 M)(15 M)(15.4 M)
BCLI
(2.4 M)(3.9 M)(3.4 M)(4.9 M)(9.2 M)(8.5 M)(5 M)(5 M)(13.9 M)(23.3 M)(31.8 M)(32.6 M)

Immunovant and related stocks such as Brickell Biotech, Bellus Health, Mustang Bio, Bridgebio Pharma, Moleculin Biotech, Amicus Therapeutics, Bioatla, Biocardia, and Brainstorm Cell Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Immunovant financial statement analysis. It represents the amount of money remaining after all of Immunovant operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Immunovant Competitive Analysis

The better you understand Immunovant competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Immunovant's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Immunovant's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
IMVT
BBI
BLU
MBIO
BBIO
MBRX
FOLD
BCAB
BCDA
BCLI
 2.36 
 8.27 
Immunovant
 1.79 
 0.55 
Brickell
 0.82 
 6.14 
Bellus
 0.91 
 2.19 
Mustang
 1.61 
 46.13 
Bridgebio
 3.89 
 2.72 
Moleculin
 0.95 
 10.42 
Amicus
 0.99 
 28.69 
Bioatla
 0.34 
 2.94 
Biocardia
 0.96 
 3.10 
Brainstorm
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Current Valuation
Cash Flow from Operations
Operating Margin
Retained Earnings
Current Asset
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Short Ratio
Market Capitalization
Price to Sales
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Immunovant Competition Performance Charts

Complement your Immunovant position

In addition to having Immunovant in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. Climate Change theme has 37 constituents.
View All  Next Launch Climate Change
Please see Immunovant Correlation with its peers. Note that the Immunovant information on this page should be used as a complementary analysis to other Immunovant's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Immunovant Stock analysis

When running Immunovant price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
The market value of Immunovant is measured differently than its book value, which is the value of Immunovant that is recorded on the company's balance sheet. Investors also form their own opinion of Immunovant's value that differs from its market value or its book value, called intrinsic value, which is Immunovant's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunovant's market value can be influenced by many factors that don't directly affect Immunovant underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunovant's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunovant value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunovant's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.